Evidence map›Paper›PMID 32391126›Full record

ArticleOncotarget2020

Correction: Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation.

Shao-Qian Sun, Xiaobin Gu, Xian-Shu Gao, Yi Li, Hongliang Yu, Wei Xiong, Hao Yu, Wen Wang, Yingbo Li, Yingqi Teng and 1 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Shao-Qian Sun *Department of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China.
Xiaobin Gu *Department of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China.
Xian-Shu GaoDepartment of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China.
Yi LiState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.
Hongliang YuDepartment of Radiation Oncology, Jiangsu Cancer Hospital Affiliated with Nanjing Medical University, Nanjing, China.
Wei XiongTangshan People's Hospital, Hebei, China.
Hao YuDepartment of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China.
Wen WangDepartment of Radiation Oncology, Peking University First Hospital, Peking University, Beijing, China.
Yingbo LiState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.
Yingqi TengBeijing Reciproca Pharmaceutical Co. Ltd., Beijing, China.
Demin ZhouState Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[This corrects the article DOI: 10.18632/oncotarget.10347.].

Identifiers

PMID32391126
PMCPMC7197445

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.